pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
821
stories
2d
EAK Distribution LLC Recalls HOME GROWN Green Sprouting Calabrese Broccoli Seeds, 8 oz, Heirloom Because of Possible Health Risk
fda recalls
2d
NIH rolling out streamlined website to help public find information more easily
stat
2d
Foghorn cuts 40% of workforce
biospace
2d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
2d
Varda raises $251M to leverage gravity in space for drug production
biospace
3d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
3d
US government launches AI-driven programs to overhaul clinical trials
biospace
3d
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
biospace
3d
Roche launches simultaneous screening test for SMA, SCID and SCD
fiercebiotech
3d
Opinion: Claude analyzed my genome in 30 minutes. Now we need standards for the results
stat
3d
STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
stat
4d
Gias Foods, Inc. Recalls Bettergoods Authentic Italian Lemon Alfredo Fettuccine Because of Possible Health Risk
fda recalls
4d
STAT+: Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
stat
4d
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
biospace
4d
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
4d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
4d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
4d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
4d
Opinion: STAT+: What to think about those mice with half-human brains
stat
4d
Opinion: America’s biotech race with China must be won at home
stat
5d
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
fiercebiotech
5d
Beam sues 2 biotechs, alleging theft of base editing trade secrets
biopharma dive
5d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
5d
UniQure tumbles with latest data for Huntington’s gene therapy
biopharma dive
5d
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
biospace
5d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
5d
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
5d
Opinion: Massive SNAP cuts could mean more children are separated from their families
stat
5d
Opinion: Child health is the national security crisis we keep ignoring
stat
5d
Why MAHA wants to make health data much more accessible
stat
← prev
page 1 of 28
next →
